Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
cancer drugs
Biotech
Lilly oncology head weighs in on FDA cancer drug policies
Lilly’s oncology chief, Jake Van Naarden, suggested that the FDA's policies on clinical trial crossover and high U.S. enrollment are not compatible.
Angus Liu
Oct 21, 2025 11:53am
Vivace hits high note in midstage mesothelioma trial
Oct 19, 2025 10:30am
French antibody biotech draws in $122M for push to clinic
Oct 16, 2025 11:19am
Tubulis touts $361M series C as next-gen ADC data drop nears
Oct 15, 2025 5:01am
Australian biotech partners with Pi Health for cancer trial
Sep 4, 2025 8:30am
Servier hands Ideaya $210M upfront for ex-US rights to PKC asset
Sep 2, 2025 3:02pm
